Japan and South Korea are ranked low in the Gender Gap Index, and the ratio of female faculty members at universities is low. The ratio of female professors at universities is assumed to be lower than the ratio of female medical professionals; however, the details remain unknown. Consequently, this study aimed to examine sex disparity among professors in the pharmacy departments of universities in Japan and South Korea. Furthermore, the characteristics of Japanese and South Korean pharmacy departments were examined to explore the differences and sex disparity. This study was conducted based on publicly available information from the websites of each university’s pharmacy department as of November 1, 2023. Sex was determined from first names or photographs. This study was conducted following the STROBE guidelines, and no ethical review or consent was required. This study included 73 universities in Japan and 35 universities in South Korea. The proportion of female professors in university pharmacy departments was 12.5% in Japan and 32.9% in South Korea. A total of 1,965 pharmacy professors were identified in Japan and South Korea. Of these, 1,527 were from Japan and 438 were from South Korea. The estimated ratio of professors to million individuals in Japan was 12.28, compared to 8.51 in South Korea. This indicated that Japan had approximately 1.4 times as many professors as South Korea after correction for population.  The proportion of female professors in both countries was <50%. Japan had significantly fewer female professors than South Korea, suggesting that women’s advancement in university pharmacy departments was lagging in Japan. Additionally, South Korea’s higher number of female professors specializing in clinical research may suggest that women with clinical practice experience in hospitals or pharmacies were becoming university professors.

The authors have declared no competing interest.

Yes

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study did not require institutional review board approval or patient informed consent because it was based on publicly available information and included no patient records.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data available on request from the researchers after approval by the author. Basically, the data could be available, however the data in this study was created originally by the authors, and the authors would like to know who will use the data and how.